DECLOMYCIN demeclocycline hydrochloride is an antibiotic isolated from a mutant strain of Streotomyces aureofaciens. Chemically it is7-Chloro-4.(dimethylamino)-1,4,4a,5,5a,6.11,12a-octahydro-3,6,10.12.12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamidemonohydrochloride.

Its structural formula is:

DECLOMYCIN Tablets for oral administration contain 150 mg or 300 mg of demeclocycline hydrochloride and the following inactive ingredients: Alginic Acid, Corn Starch, Ethylcellulose, Hypromellose, Magnesium Stearate, D&C Red 7, Sorbitol, Titanium Dioxide, FD&C Yellow 10 and other ingredients. May also contain Sodium Lauryl Sulfate.

Last updated on RxList: 6/18/2008

DECLOMYCIN (demeclocycline hydrochloride) is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below;

Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae; Lymphogranuloma venereum due to Chlamydia trachomatis; Psittacosis (Ornithosis) due to Chlamydia psittaci;

Trachoma due to Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis, Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis, Relapsing fever due to Borrelia recurrentis; Chancroid caused by Haemophilus ducreyi, Plague due to Yersinia pestis, Tularemia due to Francisella tularensis; Cholera caused by Vibrio cholerae, Campylobacter fetus infections caused by Campylobacter fetus; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis; Granuloma inguinale caused by Calymmatobacterium granulomatis; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species; Acinetobacter species;

Respiratory tract infections caused by Haemophilus influenzae, Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae, Skin and skin structure infections caused by Staphylococcus aureus.

(Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections:

Uncomplicated urethritis in men due to Neisseria gonorrhoeae, and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae; Syphilis caused by Treponema pallidum subspecies pallidum; Yaws caused by Treponema pallidum subspecies pertenue; Listeriosis due to Listeria monocytogenes; Anthrax due to Bacillus anthracis; Vincent's infection caused by Fusobacterium fusiforme; Actinomycosis caused by Actinomyces israelii, Clostridial diseases caused by Clostridium species, In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides.

In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Declomycin (demeclocycline hydrochloride) Tablets and other antibacterial drugs, Declomycin (demeclocycline hydrochloride) Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Therapy should be continued tor at least 24 to 48 hours after symptoms and fever have subsided.

Concomitant therapy: Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and by iron- containing preparations. Foods and some dairy products also interfere with absorption. Oral forms of tetracycline should be given at least 1 hour before or 2 hours after meals.

In patients with renal impairment: (See WARNINGS.) Tetracyclines should be used cautiously in patients with impaired renal function. Total dosage should be decreased by reduction of recommended individual doses and/or by extending time Intervals between doses. In patients with liver impairment Tetracyclines should be used cautiously in patients with impaired liver function. Total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses. Administration of adequate amounts of fluid with the oral formulations of tetracyclines is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. (See ADVERSE REACTIONS.)

Adults: Usual dally dose - Four divided doses of 150 mg each or two divided doses of 300 mg each.

For pediatric patients above eight years of age: Usual dally dose, 7 to 13 mg per kg body weight per day, depending upon the severity of the disease, divided into two to four doses not to exceed adult dosage of 600 mg per day.

Gonorrhea patients sensitive to penicillin may be treated with demeclocycline administered as an initial oral dose of 600 mg followed by 300 mg every 12 hours for four days to a total of 3 grams.

DECLOMYCIN® demeclocycline hydrochloride Tablets, 150 mg, are round, convex, red, film coated tablets, engraved with D11 on one side, and are supplied as follows:

NDC 14168-2865-1-Bottle of 100

DECLOMYCIN® demeclocycline hydrochloride Tablets, 300 mg, are round, convex, red, film coated tablets, engraved with D12 on one side, and are supplied as follows:

NDC 14168-2875-1 - Bottle of 48

Store at controlled room temperature 20°-25° C (68°-77°F).

NDC# 14168-2865-1-150 mg
NDC# 14168-2875-1-300 mg

Manufactured By: MOVA PHARMACEUTICAL CORPORATION, Manati, Puerto Rico 00074, USA. Marketed By: StoneBridge Pharma, LLC Duluth, GA 30097. FDA rev date: 4/22/2008

Last updated on RxList: 6/18/2008

The following reactions have been reported in patients receiving tetracyclines:

Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, pancreatitis, and inflammatory lesions (with monilial overgrowth) in the anogenital region, increases in liver enzymes, and hepatic toxicity has been reported rarely. Rarely, hepatitis and liver failure have been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines.

Instances of esophageal ulcerations have been reported in patients receiving oral tetracyclines. Most of the patients were reported to have taken the medication immediately before lying down. (See DOSAGE AND ADMINISTRATION.)

Skin: Maculopapular and erythematous rashes, erythema multiforme. Exfoliative dermatitis has been reported but is uncommon. Fixed drug eruptions and Stevens-Johnson syndrome have been reported rarely. Lesions occurring on the glans penis have caused balanitis. Pigmentation of the skin and mucous membranes has also been reported. Photosensitivity is discussed above. (See WARNINGS.)

Renal toxicity: Acute renal failure. Rise in BUN has been reported and is apparently dose related. Nephrogenic diabetes insipidus.(See WARNINGS.)

Hypersensitivity reactions: Urticaria, angioneurotic edema, polyarthralgia, anaphylaxis, anaphylactoid purpura, pericarditis, exacerbation of systemic lupus erythematosus, lupus-like syndrome, pulmonary infiltrates with eosinophilia.

Hematologic: Hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia have been reported.

CNS: Pseudotumor cerebri (benign intracranial hypertension) in adults and bulging fontanels in infants (see PRECAUTIONS-General). Dizziness, headache, tinnitus, and visual disturbances have been reported. Myasthenic syndrome has been reported rarely.

Other: When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function studies are known to occur. Very rare cases of abnormal thyroid function have been reported.

Tooth discoloration has occurred in pediatric patients less than 8 years of age (see WARNINGS), and also has been reported rarely in adults,

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillins, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin,

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective,

The concurrent use of tetracyclines and methoxyflurane has been reported to result in fatal renal toxicity. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations.

Last updated on RxList: 6/18/2008

DEMECLOCYCLINE HYDROCHLORIDE, LIKE OTHER TETRACYCLINE- CLASS ANTIBIOTICS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY, OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE DRUGS, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS.

THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY. INFANCY AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every six hours, This reaction was shown to be reversible when the drug was discontinued. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development), Evidence of embryo toxicity has also been noted in animals treated early in pregnancy. The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline may lead to azotemia, hyperphosphatemia, and acidosis. If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulation of the drug and possible liver toxicity. Under such conditions, lower than usual total doses are indicated and, if therapy is prolonged, serum level determinations of the drug may be advisable.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Phototoxic reactions can occur in individuals taking demeclocycline, and are characterized by severe burns of exposed surfaces resulting from direct exposure of patients to sunlight during therapy with moderate or large doses of demeclocycline. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur, and treatment should be discontinued at the first evidence of erythema of the skin.

Administration of DECLOMYCIN (demeclocycline hydrochloride) has resulted in appearance of the diabetes insipidus syndrome (polyuria, polydipsia and weakness) in some patients on long-term therapy. The syndrome has been shown to be nephrogenic, dose-dependent and reversible on discontinuance of therapy. Patients who are experiencing central nervous system symptoms associated with demeclocycline therapy, should be cautioned about driving vehicles or using hazardous machinery while on demeclocycline therapy.

General

Pseudo tumor cerebri (benign intracranial hypertension) in adults has been associated with the use of tetracyclines, The usual clinical manifestations are headache and blurred vision. Bulging fontanels have been associated with the use of tetracyclines in infants. While both of these conditions and related symptoms usually resolve soon after discontinuation of the tetracycline, the possibility for permanent sequelae exists.

As with other antibiotic preparations, use of this drug may result in overgrowth of non susceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy should be instituted. Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy, when indicated. Prescribing Declomycin (demeclocycline hydrochloride) Tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Laboratory Tests

In venereal diseases when coexistent syphilis is suspected, darkfield examination should be done before treatment is started and the blood serology repeated monthly for at least 4 months. In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic, should be performed. All patients with gonorrhea should have a serologic test for syphilis at the time of diagnosis. Patients treated with demeclocycline hydrochloride should have a follow-up serologic test for syphilis after 3 months.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to evaluate carcinogenic potential of demeclocycline hydrochloride have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with the related antibiotics oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors).

Although mutagenicity studies of demeclocycline hydrochloride have not been conducted, positive results in in vitro mammalian cell assays (i.e.,, mouse lymphoma and Chinese hamster lung cells) have been reported for related antibiotics (tetracycline hydrochloride and oxytetracycline). (See WARNINGS and Animal Pharmacology And Animal Toxicology.)

Demeclocycline hydrochloride had no effect on fertility when administered in the diet to male and female rats at a daily intake of 45 times the human dose.

Pregnancy

Teratogenic effects. Pregnancy Category D. (See WARNINGS.) Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. Non teratogenic effects. (See WARNINGS.)

Labor and Delivery

The effect of tetracyclines on labor and delivery is unknown.

Nursing Mothers

Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother, (See WARNINGS.)

Pediatric Use

Not for use in patients younger than eight years of age. See WARNINGS, PRECAUTIONS (General subsection) and DOSAGE AND ADMINISTRATION.

Last updated on RxList: 6/18/2008

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Tetracyclines are not removed in significant quantities by hemodialysis or peritoneal dialysis.

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or any of the components of the product formulation.

Last updated on RxList: 6/18/2008

Pharmacokinetics

The absorption of demeclocycline is slower than that of tetracycline. The time to reach the peak concentration is about 4 hours. After a 150 mg oral dose of demeclocycline tablet, the mean concentrations at 1 hour and 3 hours are 0.46 and 1.22 µg/mL (n = 6), respectively, The serum half-life ranges between 10 and 16 hours. When demeclocycline hydrochloride is given concomitantly with some dairy products, or antacids containing aluminum, calcium, or magnesium, the extent of absorption is reduced by more than 50%. Demeclocycline hydrochloride penetrates well into various body fluids and tissues. The percent of demeclocycline hydrochloride bound to plasma protein is about 40% using a dialysis equilibrium method and 90% using an ultra-filtration method. Demeclocycline hydrochloride, like other tetracyclines, is concentrated in the liver and excreted into the bile where it is found in much higher concentrations than in the blood. The rate of demeclocycline hydrochloride renal clearance (35mL/min/1.73 m²) is less than half that of tetracycline. Following a single 150 mg dose of demeclocycline hydrochloride in normal volunteers, 44% (n = 8) was excreted in urine and 13% and 46%, respectively, were excreted in feces in two patients within 96 hours as active drug.

Microbiology

The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including demeclocycline, have a similar antimicrobial spectrum of activity against a wide range of gram-negative and gram- positive organisms. Cross-resistance of these organisms to tetracyclines is common.

Demeclocycline has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.

AEEROBIC GRAM-POSITIVE MICROORGANISMS:

Bacillus anthracis
Listeria monocytogenes                                                 
Staphylococcus aureus
Streptococcus pneumoniae

AEROBIC GRAM-NEGATIVE MICROORGANISMS:

Bartonella bacilliformis
Brucella species
Calymmatobacterium granulomatis
Campylobacter fetus
Francisella tularensis
Haemophilus ducreyi
Haemophilus influenzae
Neisseria gonorrhoeae
Vibrio cholerae
Yersinia pestis

Because many strains of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are especially recommended;

Acinobacter species
Enterobacter aerogenes
Escherichia coli
Klebsiella species
Shigella species

OTHER MICROORGANISMS:

Actinomyces israelii
Borrelia recurrentis
Chlamydia psittaci
Chlamydia trachomatis
Clostridium species
Entamoeba mobs
Fusobacterium fusiforme
Mycoplasma pneumoniae
Propionibacterium acnes
Rickettsiae
Treponema pallidum subspecies pallidum
Treponema pallidum subspecies pertenue
Ureaplasma urealyticum
Shigella species

OTHER MICROORGANISMS:

Actinomyces israelii
Borrelia recurrentisChlamydia psittaci
Chlamydia trachomatis
Clostridium species
Entamoeba species
Fusobacterium fusiforme
Mycoplasma pneumoniae
Propionibacterium acnes
Rickettsiae
Treponema pallidum subspecies pallidum
Treponema pallidum subspecies pertenue
Ureaplasma urealyticum

Susceptibility Tests

Dilution Techniques

Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of demeclocycline hydrochloride or tetracycline powder.¹ The MIC values should be interpreted according to the following criteria;

For organisms other than Haemophilus species, Neisseria gonorrhoeae and Streptococcus species:²

MIC (pg/mL)	Interpretation
≤ 4	Susceptible (S)
8	Intermediate (I)
≥16	Resistant (R)
For Haemophilus and Streptococcus species:2
MIC (ug/mL)	Interpretation
≤ 2	Susceptible (S)
4	Intermediate (I)
≥ 8	Resistant (R)
For Neisseria gonorrhoeae2
MIC (ug/ml)	Interpretation
≤ 0.25	Susceptible (S)
0.5 to 1	Intermediate (I)
≥ 2	Resistant (R)

A report of "Susceptible" indicates that the pathogen is likely to be inhibited by usually achievable concentrations of the antimicrobial compound in blood. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated, This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used, This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected,

Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard demeclocycline or tetracycline powder should provide the following MIC values;2

Microorganism	MIC (µg/mL)
E. coli, ATCC 25922	1to4
E faecalis, ATCC 29212	8 to 32
H. influenzae, ATCC 49247	4 to 32
N. gonorrhoeae, ATCC 49226	0,25 to 1
S. aureus, ATCC 29213	0.25 to 1
S. pneumoniae, ATCC 49619	0.12 to 0,5

Diffusion Techniques

Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure requires the use of standardized inoculum concentrations.² This procedure uses paper disks impregnated with 30-µg tetracycline (as a class disk) or a 30-µg demeclocycline hydrochloride disk to test the susceptibility of microorganisms to demeclocycline. Reports from the laboratory providing results of the standard single-disk susceptibility test with either a 30-µg tetracycline-class disk or a 30-µg demeclocycline disk should be interpreted according to the following criteria: For organisms other than Haemophilus species, Neisseria gonorrhoeae and Streptococcus species:²

Zone Diameter (mm)	Interpretation
≥ 19	Susceptible (S)
15 to 18	Intermediate (I)
≤14 ,	Resistant (R)
For Haemophilus species:2
Zone Diameter (mm)	Interpretation
≥ 29	Susceptible (S)
26 to 28	Intermediate (I)
≤ 25	Resistant (R)

For N. gonorrhoeae2
Zone Diameter (mm)	Interpretation
≥ 38	Susceptible (S)
31 to 37	Intermediate (I)
≤ 30	Resistant (R)
For Streptococcus species:2
Zone Diameter (mm)	Interpretation
≥ 23	Susceptible (S)
19 to 22	Intermediate (I)
≤ 18	Resistant (R)

Interpretation should be as stated above for results using dilution techniques, Interpretation involves correlation of the diameter obtained in the disk test with the MIC for demeclocycline hydrochloride or tetracycline.

As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30-µg demeclocycline hydrochloride disk or the 30-µg tetracycline-class disk should provide the following zone diameters in these laboratory test quality control strains:²

Microorganism	Zone Diameter (mm)
E coli, ATCC 25922	18 to 25
H. influenzae, ATCC 49247	14 to 22
N. gonorrhoeae, ATCC 49226	30 to 42
S. aureus, ATCC 25923	24 to 30
S. pneumoniae, ATCC 49619	27 to 31

Animal Pharmacology And Animal Toxicology

Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, tetracycline P04 and methacycline; in mini pigs by doxycycline, minocycline, tetracycline POa. and methacydine; in dogs by doxycycline and minocycline in monkeys by minocycline,

Minocycline, tetracycline P04, methacycline, doxycycline, tetracycline base, oxytetracycline HCI, and tetracycline HCI were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.

Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline), in chickens (chlortetracycline), and in cats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.

REFERENCES

1.  National Committee for Clinical Laboratory Standards. (2000). "Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5 and informational supplement M100-S10." National Committee for Clinical Laboratory Standards, Wayne, PA.

2.  National Committee for Clinical Laboratory Standards. (2000). "Performance standards for antimicrobial disk susceptibility tests. Approved Standard m²-A7," National Committee for Clinical Laboratory Standards, Wayne, PA.

3.  National Committee for Clinical Laboratory Standards. (2002). "Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. M100-S12." National Committee for Clinical Laboratory Standards, Wayne, PA.

Last updated on RxList: 6/18/2008

Photosensitivity manifested by an exaggerated sunburn reaction has been observed In some Individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema. Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective. (See DRUG INTERACTIONS,) Patients should be Informed that demeclocycline hydrochloride tablets should be taken at least 1 hour before meals or 2 hours after meals (See DOSAGE AND ADMINISTRATION.) Unused supplies of tetracycline antibiotics should be discarded by the expiration date. Patients who are experiencing headache, dizziness, lightheadedness, vertigo, or blurred vision while on demeclocycline therapy, should be cautioned about driving vehicles or using hazardous machinery while receiving demeclocycline therapy. (See WARNINGS.) Patients should be counseled that antibacterial drugs, Including Declomycin (demeclocycline hydrochloride) Tablets, should only be used to treat bacterial Infections. They do not treat viral Infections (e.g., the common cold). When Declomycin (demeclocycline hydrochloride) Tablets are prescribed to treat a bacterial Infection, patients should be told that although it is common to feel better early In the course of therapy, the medication should be taken exactly as directed.

Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the Immediate treatment and (2) Increase the likelihood that bacteria will develop resistance and will not be treatable by Declomycin (demeclocycline hydrochloride) Tablets or other antibacterial drugs in the future.

Last updated on RxList: 6/18/2008

IMPORTANT NOTE: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your health care professional. Always seek the advice of your health care professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your health care professional. This information does not contain any assurances that this product is safe, effective, or appropriate for you.

DEMECLOCYCLINE - ORAL

(dem-eh-klo-SYE-kleen)

COMMON BRAND NAME(S): Declomycin

USES: Demeclocycline is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria.

This antibiotic treats only bacterial infections. It will not work for viral infections (e.g., common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This drug may also be used for treating a certain hormone imbalance (Syndrome of Inappropriate Antidiuretic Hormone-SIADH) which causes your body to retain water and your urine to be more concentrated than it should be. Demeclocycline works by increasing the amount of water in your urine to more normal levels.

HOW TO USE: Take this medication by mouth, usually 2 to 4 times a day or as directed by your doctor. Demeclocycline works best when taken on an empty stomach at least 1 hour before or 2 hours after a meal. Take each dose with a full glass of water (8 ounces or 240 milliliters) unless your doctor directs you otherwise. Do not lie down for 30 minutes after taking this drug. For this reason, do not take it right before bedtime.

If stomach upset occurs, ask your doctor if you can take this medication with food.

Take this medication 2 to 3 hours before or after taking any medications containing magnesium, aluminum, or calcium. Some examples include quinapril, certain forms of didanosine (chewable/dispersible buffered tablets or pediatric oral solution), vitamins/minerals, and antacids. Dairy products (e.g., milk, yogurt), calcium-enriched juice, sucralfate, bismuth subsalicylate, iron, and zinc are also included. These products bind with demeclocycline, preventing its full absorption.

The dosage is based on your medical condition and response to treatment. When treating children over 8 years of age, the dosage is also based on weight. For the treatment of infection, children should not take more than 600 milligrams of this medication per day.

This medication works best when the amount of medicine in your body is kept at a constant level. Therefore, take this drug at evenly spaced intervals.

If you are taking this medication to treat an infection, continue to take it until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may result in a return of the infection.

Inform your doctor if your condition persists or worsens. If you are using this medication to treat SIADH, you should notice an increase in the amount of urine within 5 days.

SIDE EFFECTS: Diarrhea, loss of appetite, nausea, vomiting, headache, dizziness, lightheadedness, or rectal discomfort may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: sunburn-like skin reaction (sun sensitivity), darkening of the skin and other areas of the body (e.g., lips, inside of the mouth), difficult/painful swallowing, unusual increase in the amount of urine (except for the expected increase in urination if you are treating SIADH), unusual decrease in the amount of urine or no urine, unusual thirst, weakness, unusual tiredness, brown/gray tooth discoloration.

Tell your doctor immediately if any of these rare but very serious side effects occur: hearing changes (e.g., ringing in the ears, decreased hearing), persistent/severe headache, vision changes (e.g., blurred vision), easy bruising/bleeding, new signs of infection (e.g., persistent sore throat, fever, chills), stomach/abdominal pain, persistent nausea/vomiting, yellowing eyes/skin, dark urine.

This medication may rarely cause a severe intestinal condition (pseudomembranous colitis) due to a type of resistant bacteria. This condition may occur during treatment or weeks to months after treatment has stopped. Do not use anti-diarrhea products or narcotic pain medications if you have the following symptoms because these products may make them worse. Tell your doctor immediately if you develop: persistent diarrhea, abdominal or stomach pain/cramping, blood/mucus in your stool.

Use of this medication for prolonged or repeated periods may result in oral thrush or a new vaginal yeast infection. Contact your doctor if you notice white patches in your mouth, a change in vaginal discharge, or other new symptoms.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any of the following symptoms of a serious allergic reaction, including: rash, skin sores/blisters, itching, swelling, severe dizziness, trouble breathing, new or worsening swelling/pain in the joints, chest pain, fast/irregular heartbeat.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

Contact your doctor for medical advice about side effects. The following numbers do not provide medical advice, but in the US you may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088. In Canada, you may call Health Canada at 1-866-234-2345.

PRECAUTIONS: Before taking demeclocycline, tell your doctor or pharmacist if you are allergic to it; or to other tetracycline medication (e.g., doxycycline, minocycline, tetracycline); or if you have any other allergies.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, liver disease, problems swallowing, esophagus problems (e.g., esophageal ulcers, hiatal hernia, acid reflux disease-GERD), lupus, a certain hormone imbalance called "water diabetes" (diabetes insipidus).

This drug may make you dizzy or lightheaded. Use caution while driving, using machinery, or taking part in any activity that requires alertness. Limit alcoholic beverages.

This medication may make you more sensitive to the sun. Avoid prolonged sun exposure, tanning booths, and sunlamps. Use a sunscreen and wear protective clothing when outdoors.

Before having surgery, tell your doctor or dentist that you are using demeclocycline.

This medication should not be used in children younger than 8 years of age because it may cause permanent tooth discoloration and other problems. Tooth discoloration has also occurred in older children and young adults. Consult your doctor for more information.

This medication is not recommended for use during pregnancy. It may harm an unborn baby. Consult your doctor for more details and to discuss reliable forms of birth control.

This medication passes into breast milk in very small amounts. While there have been no reports of harm to nursing infants, consult your doctor before breast-feeding.

DRUG INTERACTIONS: See also How to Use section.

Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with them first.

This drug should not be used with the following medications because very serious interactions may occur: certain retinoids (acitretin, isotretinoin, tretinoin), strontium ranelate.

If you are currently using any of these medications listed above, tell your doctor or pharmacist before starting demeclocycline.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: digoxin, kaolin pectin, live bacterial vaccines, penicillins, warfarin.

This medication may decrease the effectiveness of combination-type birth control pills. This can result in pregnancy. Ask your doctor or pharmacist for details. Discuss whether you should use additional reliable birth control methods while taking this medication.

This product can affect the results of certain lab tests (e.g., some urine tests for sugar), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center.

NOTES: Do not share this medication with others.

This medication has been prescribed for your current condition only. Do not use it later for another infection unless told to do so by your doctor. A different medication may be necessary in that case.

With prolonged use or if this medication is used to treat SIADH, laboratory and/or medical tests (e.g., complete blood count, kidney and liver function tests, mineral levels) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

STORAGE: Store at room temperature between 68-77 degrees F (20-25 degrees C) in a tightly closed container away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Taking outdated demeclocycline can result in serious illness. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

Information last revised July 2008 Copyright(c) 2008 First DataBank, Inc.